There is no amount of money worth taking a trip on this train wreck. There are far more unhappy people here than most realize. Many of them just put on a happy face which is what’s require but if you have other options then fully explore them before making the decision to come here. You probably could make a nice bonus selling wegovy but it’s not well covered at all. It’s essentially being given away for free at a gigantic discount and that won’t last very much longer. Also, don’t believe the BS about being a specialty rep. You sell the same product as primary care reps which will be written and covered when your customers can’t get your product approved and paid for. Check out the pipeline was well. Not much doing. The product with the most potential is weekly deg and that is going to fall flat on it face. Regardless of what will come out, it will be overpriced and under covered. That’s the novo way.
Obesity Division will become extinct with the upcoming intro of Lilly's drug. Bye bye Wegovy.
Lol. Try the diabetes division. Mounjaro passed Ozempic in just a few weeks. We’ll be just fine over here. Plenty of patients to go round for both companies and we have the advantage of 8 years in a market they have never sold in. And in a couple of years, we’ll have a drug that’s more effective than tirz.
So the same as all your Ozempic business that you want to take credit for then.
Just responding to your incorrect statement on the Monjuaro launch compared to Ozempic. Yes it surpassed Ozempic only bc they are writing it off label. Hence their PI change. It’s all semaglutide…how long until we promote as one sales force?? When I sold Saxenda we were initially with the diabetes sales team.
Is it in the pipeline? Also, if Novo is such a great company then why are they constantly launching products after Lilly? Novo is a poorly run company and that’s the bottom line.
Novo is poorly run. No argument there. I’m comparing divisions within novo. Diabetes has around 2000 reps in a highly competitive market. We have 250, soon to be 325ish in a market where we’ve basically been the only company for 8 years. Wegovy costs 50% more than Ozempic and the obesity market is 5x larger. The second we get Medicare and Medicaid, the market is projected to balloon to 50 billion. In short, obesity is the future of this company, period.
